Synlogic stock.

CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to SYNB1934 for the treatment of phenylketonuria (PKU). “We are …

Synlogic stock. Things To Know About Synlogic stock.

Synlogic is a biotechnology company that designs Synthetic Biotics, living probiotics that treat diseases with Synthetic Biotic pipeline. The web page provides stock quote, chart, news releases, events, and corporate documents of Synlogic, as well as investor resources and contact information.Discover historical prices for SYBX stock on Yahoo Finance. View daily, weekly or monthly format back to when Synlogic, Inc. stock was issued. View the latest Synlogic Inc. (SYBX) stock price, news, historical charts, analyst ratings and financial information from WSJ. Synlogic, Inc. Doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its ...Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage drug discovery and development company applying synthetic biology to beneficial microbes to develop novel living medicines, today announced the appointment of Antoine Awad as Head of Technical Operations, and the expansion of its manufacturing capabilities to produce clinical trial …

Aoife Brennan, Synlogic CEO. Synlogic “We have been working with Ginkgo for over two years now,” said Aoife Brennan, Synlogic CEO. “We initially started with a pilot project that went so ...

Synlogic's SYNB1353 in December 2022 received RPDD for the potential treatment of homocystinuria or HCU. For More Such Health News, visit rttnews.com SHARE THIS POST

View live Synlogic, Inc. chart to track its stock's price action. Find market predictions, SYBX financials and market news.The value each SYBX share was expected to gain vs. the value that each SYBX share actually gained.. Synlogic (SYBX) reported Q3 2023 earnings per share (EPS) of-$2.57, missing estimates of -$2.18 by 17.89%.In the same quarter last year, Synlogic's earnings per share (EPS) was-$3.73.Synlogic is expected to release next earnings on …The Investor Relations website contains information about Synlogic's business for stockholders, potential investors, and financial analysts. Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.

Synlogic has also developed two drug candidates through a research collaboration with Ginkgo Bioworks: SYNB1353, designed to consume methionine for the potential treatment of HCU, and SYNB2081, designed to lower uric acid for the potential treatment of gout.

Analyst Keay Nakae of Chardan Capital reiterated a Buy rating on Synlogic (SYBX – Research Report), with a price target of $35.00. Keay Nakae’s Buy rating for Synlogic is rooted in several ...

Synlogic, Inc. CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed ...You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.INMB stock currently trades for $7.80 and reached a 52-week high of $11.78 while carrying an average target stock price of $18.00. Synlogic (SYBX) Biotechnology stocks, biomedical stocks.CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reported financial results for the fourth quarter and full year ending December 31, 2022 and provided a business update. “Last year was a tremendous year for …Figure 5: Synlogic Stock Chart (source: finviz) Thus, Synlogic looks like a good value at current levels, although, obviously, still a high-risk investment due to the early stages of its assets.The last twelve months weren't great for Synlogic shares, which cost holders 12%, while the market was up about 15%. Of course the long term matters more than the short term, and even great stocks ...In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Synlogic (SYBX – Research Report), with a price target of $24.00. Ed Arce has given his Buy rating due to a ...

Synlogic is a clinical-stage biotechnology company developing medicines through its proprietary approach to synthetic biology. Synlogic's pipeline includes its lead program in phenylketonuria (PKU), which has demonstrated proof of concept with plans to start a pivotal, Phase 3 study in the first half of 2023, and additional novel drug …Ginkgo has purchased 6,340,771 shares of Synlogic common stock as well as pre-funded warrants to purchase up to 2,548,117 shares of Synlogic common stock, both at a price of $9.00 per share. Gross proceeds to Synlogic are approximately $80 million. The transactions were executed and closed on June 11, 2019.Summary of all time highs, changes and price drops for Synlogic; Historical stock prices; Current Share Price: US$2.56: 52 Week High: US$16.50: 52 Week Low: …Mar 17, 2022 · Fourth Quarter 2021 Financial Results. As of December 31, 2021, Synlogic had cash, cash equivalents, and marketable securities of $136.6 million. Revenue was $0.6 million for the three months ... Synlogic, Inc. CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed ...Based upon its current operating plan and balance sheet as of December 31, 2022, Synlogic expects to have sufficient cash to be able to fund operations into the second half of 2024. About Synlogic Synlogic is the leading company advancing therapeutics based on synthetic biology. Synlogic’s pipeline includes its lead program in phenylketonuria ...On August 25, 2017, in connection with, and prior to the completion of the Merger, Mirna effected a reverse stock split of its common stock (the “Reverse Stock Split”), and on August 28, 2017, immediately after completion of the Merger, Mirna changed its name to “Synlogic, Inc.” (NASDAQ: SYBX).

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 8% and 3.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?Synlogic Announces Reverse Stock Split. CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non ...

Synlogic, Inc. CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S ...Get the latest Synlogic, Inc. (SYBX) stock news and headlines to help you in your trading and investing decisions.Analyst Keay Nakae of Chardan Capital reiterated a Buy rating on Synlogic (SYBX – Research Report), with a price target of $35.00. Keay Nakae’s Buy rating for Synlogic is rooted in several ...Synlogic's SYNB1353 in December 2022 received RPDD for the potential treatment of homocystinuria or HCU. For More Such Health News, visit rttnews.com SHARE THIS POSTThe first big announcement that META stock fans will want to note is details on the Meta Quest 3. This is the company’s VR headset that offers 10x the number of pixels as the Meta Quest 2 for $500.Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.Founded Date 2014. Founders Alison Silva, Ankit Mahadevia, Dean Falb, Jim Collins, Timothy K. Lu. Operating Status Closed. Last Funding Type Post-IPO Equity. Legal Name Synlogic, Inc. Stock Symbol NASDAQ:SYBX. Company Type For Profit. Contact Email [email protected]. Phone Number (617)401-9975.Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.

Third Quarter 2023 Financial Results and Financial Outlook. As of September 30, 2023, Synlogic had cash, cash equivalents and short-term investments of $33.4 million, not inclusive of the October financing of $19.6 million (net), and an additional $2.5 million earned from the Roche research collaboration milestone announced in November.

Synlogic uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunological diseases.

Nov 27, 2023 · What is Synlogic's consensus rating and price target? According to the issued ratings of 2 analysts in the last year, the consensus rating for Synlogic stock is Buy based on the current 2 buy ratings for SYBX. The average twelve-month price prediction for Synlogic is $82.50 with a high price target of $90.00 and a low price target of $75.00. Dec 1, 2023 · Based on short-term price targets offered by three analysts, the average price target for Synlogic, Inc. comes to $21.67. The forecasts range from a low of $6.00 to a high of $35.00. The average ... Oct 2, 2023 · The latest Synlogic stock prices, stock quotes, news, and SYBX history to help you invest and trade smarter. CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to SYNB1934 for the treatment of phenylketonuria (PKU). “We are …Synthetic biology is an entirely new strategy in drug development, affording us the opportunity to design selective and potent living medicines to treat disease. With a team of experienced scientists and executives at the helm, Synlogic is forging new ground to advance this approach and design novel therapeutics to treat unmet medical needs.Synlogic Stock Probability Of Bankruptcy ... Stocks USA . ... Synlogic Probability Of Bankruptcy is used to show its chance of financial distress over the next two ...Dec 1, 2023 · Synlogic to Implement 1-for-15 Reverse Stock Split Sep. 28: MT Earnings Flash (SYBX) SYNLOGIC Posts Q2 Revenue $35,000 Aug. 10: MT Synlogic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 Aug. 10: CI Support, Risk & Stop-loss for Synlogic Inc stock. On the downside, the stock finds support just below today's level from accumulated volume at $2.14 and $2.07. There is a natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level.

Synlogic has a clinical trial program, called Synpheny, to evaluate labafenogene marselecobac (previously known as SYNB1934), this potential therapy. To receive updates about our PKU program, including our pivotal Phase 3 trial, Synpheny-3, sign-up to stay connected. You can also learn more about Synpheny-3 at www.pkuresearchstudy.com.Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -8.70% and 93.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Oct 20, 2022 · Synlogic was spun out of MIT and uses technology developed by Drs. Tim Lu and Jim Collins. Synlogic was founded in 2014 and became a public company via a reverse merger in 2017. The first ... Instagram:https://instagram. 1776 to 1976 d quarter worthlearn day tradingbtf stockbest banks virginia Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic's approach to Synthetic Biotics to develop therapeutics to address a wide range of diseases including: inborn errors of metabolism and inflammatory and immune disorders; our expectations about sufficiency of our existing cash ... nyse gtlsbest free stock charts Stock Quote & Chart Analyst Coverage. Corporate Governance. Governance Highlights Leadership Board of Directors Committee Composition Board Diversity Matrix. ... Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting. March 20, 2023.If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets. light speed trader CAMBRIDGE, Mass., March 25, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today reported financial results for the fourth quarter and full year ended December 31, 2020, and provided an update on programs and progress.Based upon its current operating plan and balance sheet as of December 31, 2022, Synlogic expects to have sufficient cash to be able to fund operations into the second half of 2024. About Synlogic Synlogic is the leading company advancing therapeutics based on synthetic biology. Synlogic’s pipeline includes its lead program in phenylketonuria ...